Loading search results
A Multicentric Observational Study on the Removal of Protein-Bound Uremic Retention Solutes in Nocturnal Hemodialysis: A Cross-Sectional Analysis
Sponsor study identifier
observational
120
2 countries
4
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2008
Actual (reported)Study Completion
December 2008
Actual (reported)Although remarkable progress has been made, chronic kidney disease still poses a major burden on both individual patients, as well as on society as a whole. There is a strong inverse relationship between decreasing renal function, as estimated by glomerular filtration rate, and mortality rate, especially death due to cardiovascular disease. The exact cause(s) remain to be elucidated. Uremic toxins might play an important role. In the course of decreasing renal function the concentration of numerous intracellular and extracellular compounds vary from the non-uremic state. But still increasing number of uremic retention solutes are being identified. Renal replacement strategies aim to remove potentially harmful substances from the body. Traditionally much attention has been paid to small water-soluble molecules such as urea nitrogen and creatinine. Based on the results of the recent HEMO and ADEMEX studies, increases of small water-soluble solute removal above the level reached with modern dialysis techniques - hemodialysis, peritoneal dialysis (HD, PD) - seem not to be advantageous with regard to patient outcome. These findings may point to the importance of other distinct groups of uremic retention solutes. In view of the data described above, protein-bound solutes might be good candidates. Several advantages of long duration hemodialysis have been observed, including a better control of blood pressure by decreasing extracellular fluid volume, lowering peripheral vascular resistance and improving endothelium-dependent and -independent vasodilation. A normalization of heart rate variability and improvement of left-ventricular function was noted as well. Furthermore, anemia control has been shown to be easier and several nutritional parameters improved in patients treated with long duration HD. The therapy results in higher small water-soluble solute removal, phosphate removal and greater elimination of larger molecules (e.g. β2-microglobulin). It seems an appealing question whether a better control of the serum levels of protein-bound solutes can be achieved by long duration (nocturnal) hemodialysis. This might be another advantage of this therapeutic modality, or may even in part explain the better outcome of patients treated this way. The study compares intermittent hemodialysis with long nocturnal hemodialysis with respect to serum concentrations of several protein bound uremic toxins, as well as solute removal.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
December 28, 2006
Actual (reported)December 29, 2006
Actual (reported)December 2008
Actual (reported)December 2008
Actual (reported)removal of protein-bound retention solutes
1 dialysis session
hemodialysis twice weekly 4 hours
nocturnal dialysis twice weekly 8 hours
nocturnal hemodialysis, 8 hours every other night
nocturnal hemodialysis, 8 hours, six times per week
group 1: twice weekly, four hours
group 2: twice weekly, eight hours
Maintenance hemodialysis patients
Monash Medical Centre
Clayton, Victoria, 3168, Australia
Geelong Hospital
Geelong, Victoria, 3220, Australia
Virga Jesse Ziekenhuis
Hasselt, Limburg, 3500, Belgium
Universitaire Ziekenhuizen Leuven
Leuven, Vlaams-Brabant, 3000, Belgium
Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int. 2006 Mar;69(6):1081-7. doi: 10.1038/sj.ki.5000115.
Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis. 2002 Aug;40(2):339-47. doi: 10.1053/ajkd.2002.34518.
serum, urine, dialysate
Björn KI Meijers, MD
Universitaire Ziekenhuizen KU Leuven
Pieter Evenepoel, MD, PhD
Universitaire Ziekenhuizen KU Leuven
Tom Dejagere, MD
Virga Jesse Ziekenhuis
Nigel Toussaint, MD
Geelong Hospital
120 participants (actual enrollment reported by the registry).
First Submitted
December 28, 2006
First Posted
December 29, 2006
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
group 3: every other day, eight hours
group 4: six days a week, eight hours
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Pierratos A. Daily nocturnal home hemodialysis. Kidney Int. 2004 May;65(5):1975-86. doi: 10.1111/j.1523-1755.2004.00603.x. No abstract available.
Primary Completion
December 2008
Actual (reported)Study Completion
December 2008
Actual (reported)Last Updated
March 5, 2009
Record last verified: 2009-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: